+

WO2004015390A3 - Proteines cibles du cancer du poumon et utilisations associees - Google Patents

Proteines cibles du cancer du poumon et utilisations associees Download PDF

Info

Publication number
WO2004015390A3
WO2004015390A3 PCT/US2003/024698 US0324698W WO2004015390A3 WO 2004015390 A3 WO2004015390 A3 WO 2004015390A3 US 0324698 W US0324698 W US 0324698W WO 2004015390 A3 WO2004015390 A3 WO 2004015390A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
proteins
target proteins
cancer target
provides
Prior art date
Application number
PCT/US2003/024698
Other languages
English (en)
Other versions
WO2004015390A2 (fr
Inventor
Stephen Hoffman
Ruobing Wang
Gangadharan Subramanian
Original Assignee
Applera Corp
Stephen Hoffman
Ruobing Wang
Gangadharan Subramanian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applera Corp, Stephen Hoffman, Ruobing Wang, Gangadharan Subramanian filed Critical Applera Corp
Priority to AU2003258134A priority Critical patent/AU2003258134A1/en
Publication of WO2004015390A2 publication Critical patent/WO2004015390A2/fr
Publication of WO2004015390A3 publication Critical patent/WO2004015390A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne cinq protéines cibles du cancer du poumon qui sont exprimées de manière différentielle dans des cellules ou des tissus du cancer du poumon. L'invention concerne également une méthode de détection du cancer du poumon. L'invention concerne en outre un vaccin de prévention et de traitement du cancer du poumon. Ce vaccin comprend des peptides immunogènes dérivés desdites cinq protéines et analogues de celles-ci. L'invention concerne enfin des anticorps qui ciblent de manière spécifique les protéines du cancer du poumon, et leur utilisation diagnostique et thérapeutique.
PCT/US2003/024698 2002-08-09 2003-08-08 Proteines cibles du cancer du poumon et utilisations associees WO2004015390A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003258134A AU2003258134A1 (en) 2002-08-09 2003-08-08 Lung cancer target proteins and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40205702P 2002-08-09 2002-08-09
US60/402,057 2002-08-09

Publications (2)

Publication Number Publication Date
WO2004015390A2 WO2004015390A2 (fr) 2004-02-19
WO2004015390A3 true WO2004015390A3 (fr) 2007-12-13

Family

ID=31715780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024698 WO2004015390A2 (fr) 2002-08-09 2003-08-08 Proteines cibles du cancer du poumon et utilisations associees

Country Status (2)

Country Link
AU (1) AU2003258134A1 (fr)
WO (1) WO2004015390A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd Peptides
BR112021008888A2 (pt) * 2018-11-07 2021-08-17 Follicum Ab fragmentos de peptídeos para o tratamento de diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147187A (en) * 1994-03-24 2000-11-14 Ludwig Institute For Cancer Research Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147187A (en) * 1994-03-24 2000-11-14 Ludwig Institute For Cancer Research Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof

Also Published As

Publication number Publication date
AU2003258134A8 (en) 2004-02-25
AU2003258134A1 (en) 2004-02-25
WO2004015390A2 (fr) 2004-02-19

Similar Documents

Publication Publication Date Title
WO2000061612A3 (fr) Composes et procedes de therapie et de diagnostic du cancer du poumon
WO1999047674A3 (fr) Composes et methodes therapeutiques et diagnostiques du cancer du poumon
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1999038973A3 (fr) Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
WO2003086308A3 (fr) Compositions et procedes pour le diagnostic et le traitement de l'infection du virus de l'herpes simplex
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
WO2002057741A3 (fr) Anticorps monoclonaux et antigenes de surface pour la detection et le traitement du cancer a petites cellules (sclc)
WO2004067023A3 (fr) Peptides derives de la survivine et leur utilisation
WO1997025426A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
WO1999033869A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
WO2005049073A3 (fr) Proteines appartenant a la famille bcl-2, fragments associes, et utilisation therapeutique de ces proteines et fragments sur des patients atteints du cancer
AU2002319867A1 (en) Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO1998045328A3 (fr) Compositions therapeutiques et diagnostiques du carcinome mammaire et methodes afferentes
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
WO2000061756A3 (fr) Composes pour l'immunotherapie et le diagnostic du cancer du sein et procedes d'utilisation
WO2002077176A3 (fr) Proteines presentant une expression aberrante dans des tumeurs microdissequees capturees au laser
WO2002002131A3 (fr) Compositions et methodes de diagnostic et de traitement de l'infection du virus de l'herpes
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
WO2004015390A3 (fr) Proteines cibles du cancer du poumon et utilisations associees
WO2006023598A3 (fr) Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
WO2005123760A3 (fr) Traitement du cancer
WO2000061753A3 (fr) Compositions et methodes de depistage et de traitement du cancer du sein
WO2004013631A3 (fr) Compositions et methodes de diagnostic et de traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载